Prevalence and Management of Obesity in U.S. Adults With Type 1 Diabetes.
作者信息
Fang Michael, Echouffo-Tcheugui Justin B, Selvin Elizabeth
机构信息
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Division of Endocrinology, Diabetes and Metabolism, Johns Hopkins School of Medicine, Baltimore, Maryland.
出版信息
Ann Intern Med. 2023 Sep;176(9):eL230228. doi: 10.7326/L23-0228.
Abstract
摘要
相似文献
1
Prevalence and Management of Obesity in U.S. Adults With Type 1 Diabetes.美国1型糖尿病成年患者肥胖症的患病率及管理
Ann Intern Med. 2023 Sep;176(9):eL230228. doi: 10.7326/L23-0228.
2
Prevalence and Management of Obesity in U.S. Adults With Type 1 Diabetes.美国1型糖尿病成年患者中肥胖症的患病率及管理
Ann Intern Med. 2023 Sep;176(9):eL230227. doi: 10.7326/L23-0227.
3
Prevalence and Management of Obesity in U.S. Adults With Type 1 Diabetes.美国1型糖尿病成年患者肥胖的患病率及管理
Ann Intern Med. 2023 Mar;176(3):427-429. doi: 10.7326/M22-3078. Epub 2023 Feb 14.
4
The Controversies in Obesity, Diabetes and Hypertension (CODHy) meeting: what is it all about?肥胖、糖尿病与高血压争议（CODHy）会议：究竟是关于什么的？
Diabetes Care. 2008 Feb;31 Suppl 2:S111-2. doi: 10.2337/dc08-s226.
5
The emergence of obesity in type 1 diabetes.1 型糖尿病患者中肥胖症的出现。
Int J Obes (Lond). 2024 Mar;48(3):289-301. doi: 10.1038/s41366-023-01429-8. Epub 2023 Dec 14.
6
Prevalence of overweight, obesity and metabolic syndrome components in children, adolescents and young adults with type 1 diabetes mellitus.1 型糖尿病患儿、青少年和年轻成人中超重、肥胖和代谢综合征成分的流行情况。
Diabetes Metab Res Rev. 2015 Jan;31(1):76-84. doi: 10.1002/dmrr.2565.
7
Obesity, insulin resistance, and type 1 diabetes mellitus.肥胖、胰岛素抵抗与1型糖尿病
Curr Opin Endocrinol Diabetes Obes. 2015 Aug;22(4):277-82. doi: 10.1097/MED.0000000000000170.
8
Estimating prevalence of diabetes in a Congolese town was feasible.在刚果镇估算糖尿病的患病率是可行的。
J Clin Epidemiol. 2011 Feb;64(2):172-81. doi: 10.1016/j.jclinepi.2010.03.014. Epub 2010 Aug 12.
9
Young children, adolescent girls and women with type 1 diabetes are more overweight and obese than reference populations, and this is associated with increased cardiovascular risk factors.患有 1 型糖尿病的幼儿、少女和成年女性比参照人群更超重和肥胖，这与心血管危险因素增加有关。
Diabet Med. 2019 Nov;36(11):1487-1493. doi: 10.1111/dme.14133. Epub 2019 Sep 20.
10
Weight gain trajectories and obesity rates in intensive and conventional treatments of type 1 diabetes from the DCCT compared with a control population without diabetes.与无糖尿病的对照人群相比，糖尿病控制与并发症试验（DCCT）中1型糖尿病强化治疗和常规治疗的体重增加轨迹及肥胖率。
Diabet Med. 2022 May;39(5):e14794. doi: 10.1111/dme.14794. Epub 2022 Jan 26.
引用本文的文献
1
Immune cell-adipose tissue crosstalk in metabolic diseases with a focus on type 1 diabetes.免疫细胞与脂肪组织在代谢性疾病中的相互作用，重点关注1型糖尿病
Diabetologia. 2025 Jun 4. doi: 10.1007/s00125-025-06437-z.
2
Determinants of Liraglutide Treatment Discontinuation in Type 1 Diabetes: A Post Hoc Analysis of ADJUNCT ONE and ADJUNCT TWO Randomized Placebo-Controlled Clinical Studies.1型糖尿病中利拉鲁肽治疗中断的决定因素：ADJUNCT ONE和ADJUNCT TWO随机安慰剂对照临床研究的事后分析
J Diabetes Sci Technol. 2025 Mar;19(2):321-331. doi: 10.1177/19322968241305647. Epub 2024 Dec 24.
3
Consensus Report on Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Treatment for Individuals With Type 1 Diabetes Using an Automated Insulin Delivery System.关于胰高血糖素样肽-1受体激动剂作为使用自动胰岛素输送系统的1型糖尿病患者辅助治疗的共识报告。
J Diabetes Sci Technol. 2025 Jan;19(1):191-216. doi: 10.1177/19322968241291512. Epub 2024 Nov 8.
4
Overweight and obesity significantly increase colorectal cancer risk: a meta-analysis of 66 studies revealing a 25-57% elevation in risk.超重和肥胖显著增加结直肠癌风险：一项对66项研究的荟萃分析显示风险升高25%至57%。
Geroscience. 2025 Jun;47(3):3343-3364. doi: 10.1007/s11357-024-01375-x. Epub 2024 Oct 8.
本文引用的文献
1
Obesity and Chronic Kidney Disease in US Adults With Type 1 and Type 2 Diabetes Mellitus.美国 1 型和 2 型糖尿病成人的肥胖与慢性肾脏病。
J Clin Endocrinol Metab. 2022 Apr 19;107(5):1247-1256. doi: 10.1210/clinem/dgab927.
2
The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).《成人 1 型糖尿病管理：美国糖尿病协会 (ADA) 与欧洲糖尿病研究协会 (EASD) 的共识报告》
Diabetes Care. 2021 Nov;44(11):2589-2625. doi: 10.2337/dci21-0043. Epub 2021 Sep 30.
3
The High Cost of Diabetes Drugs: Disparate Impact on the Most Vulnerable Patients.糖尿病药物的高昂成本：对最脆弱患者的不同影响。
Diabetes Care. 2020 Oct;43(10):2330-2332. doi: 10.2337/dci20-0039.
4
International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors.钠-葡萄糖共转运蛋白 2 抑制剂治疗的 1 型糖尿病患者糖尿病酮症酸中毒风险管理的国际共识。
Diabetes Care. 2019 Jun;42(6):1147-1154. doi: 10.2337/dc18-2316. Epub 2019 Feb 6.
5
Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial.利拉鲁肽联合胰岛素封顶治疗 1 型糖尿病患者的疗效和安全性：ADJUNCT TWO 随机试验。
Diabetes Care. 2016 Oct;39(10):1693-701. doi: 10.2337/dc16-0690. Epub 2016 Aug 4.
Zotero 插件